Author: Rodrigo Arrangoiz MS, MD, FACS, FSSO

• What was the pivotal shift from ALND to SLNB?
  • Randomized trials:
    • Milan / Veronesi, NSABP B-32, ALMANAC
  • This trials showed that SLNB achieves equivalent survival and regional control compared with ALND:
    • While markedly reducing arm morbidity and improving QoL:
      • Establishing SLNB as standard staging for cN0 disease
        • New England Journal of Medicine+2PubMed+2
• NSABP B-32 – what did it prove?
  • In > 5,600 cN0 patients:
    • SLNB alone (when SLN negative) yielded:
      • Equivalent OS and regional control to ALND:
        • With less lymphedema and sensory deficits
  • This trial anchored SLNB as safe oncologically and better for function PubMed+1
• ALMANAC – why do we still quote it?
  • The UK multicenter RCT:
    • SLNB vs standard axillary treatment:
      • Showed substantially less arm morbidity, pain, and better QoL at 12 months with SLNB:
        • An early, practice-changing morbidity signal complementing efficacy trials OUP Academic+1
• Milan (Veronesi) trial—what’s the take-home?
  • Single-center RCT:
    • SLNB safely replaced routine ALND for cN0 with durable 10-year outcomes:
      • Cementing SLNB accuracy and safety in early breast cancer
• Technique pearls that lower SLNB FNR in general?
  • Use dual-tracer mapping and retrieve ≥ 2 to 3 SLNs when possible:
    • Dual mapping reduces FNR versus single dye, and more nodes improves accuracy
• Positive SLN after upfront surgery (ALND omission)
  • ACOSOG Z0011—who can safely avoid ALND?
    • Women with cT1 to cT2, cN0 undergoing BCS + whole-breast RT, with 1 to 2 positive SLNs:
      • Had no OS benefit from ALND:
        • 10-yr OS 86.3% SLNB-alone vs 83.6% ALND
    • Today, we omit ALND for Z0011-eligible patients JAMA Network
  • Does ACOSOG Z0011 imply mandatory comprehensive RNI?
    • No:
      • Z0011 patients largely received tangential breast RT:
        • Comprehensive RNI wasn’t mandated
      • Decisions today are individualized by:
        • Tumor biology, nodal burden, and fields JAMA Network
• IBCSG 23-01—what about micrometastases (≤ 2 mm)?
• In patients with micrometastases:
  • No ALND was noninferior to ALND for long-term outcomes (10-yr DFS noninferior):
    • Supporting omission of ALND in micrometastatic disease PubMed+1
• AMAROS Trial – ART vs ALND after a positive SLN?
  • Phase III trial:
    • Axillary RT produced similar control and survival as ALND:
      • But less lymphedema (11% vs 23% at 5 yr):
        • Making ART the preferred completion strategy when axillary treatment is needed PMC+2The Lancet+2
• OTOASOR Trial – does it align with AMAROS Trial?
• Yes:
  • Single-center RCT with 8-yr follow-up:
    • RNI noninferior to ALND for control /survival after a positive SLN:
      • Reinforcing ART / RNI as an ALND alternative to limit morbidity PubMed
• SENOMAC (2024 NEJM) – what’s new versus Z0011?
  • Included mastectomy patients and broader indications: 
    • Omission of completion ALND in patients with 1 to 2 SLN macrometastases:
      • Was noninferior for survival:
        • Most received RNI
    • Expands ALND omission beyond BCS PubMed
• SENOMAC nuances – ECE, T3 tumors, men?
  • SENOMAC enrolled some patients with ECE, cT3, and men
  • Prespecified subgroup analyses did not show detriment with ALND omission:
    • Though numbers are smaller – supporting wider generalizability makadu.live
• After mastectomy with 1 to 2 positive SLNs, do I need ALND?
  • Not routinely – With planned comprehensive RNI, ALND can be omitted (AMAROS, SENOMAC) a position reflected in the 2025 ASTRO-ASCO-SSO PMRT guideline language emphasizing less invasive axillary management with nodal RT PubMed+2PubMed+2

• Omission of any axillary surgery (SLNB-omission):
  • SOUND (JAMA Oncol 2023) – who can skip SLNB entirely?
    • Women with small tumors and negative axillary ultrasound:
      • Had noninferior 5-yr distant DFS with no axillary surgery vs SLNB
    • If axillary pathology doesn’t change therapy:
      • Omission is safe
  • INSEMA (NEJM 2024/2025) – does it reinforce SLNB omission?
    • Yes:
      • In cT1 to cT2 cN0 undergoing BCS + WBRT, omitting SLNB was noninferior for invasive DFS, with fewer arm morbidities:
        • Broadening omission beyond SOUND’s entry criteria
  • Guideline impact – what does ASCO 2025 now recommend?
    • ASCO now supports SLNB omission for select postmenopausal ≥50, HR+/HER2-, G1–2, ≤2 cm tumors with negative AUS undergoing BCS + RT, when nodal status won’t alter adjuvant therapy
  • How do I counsel a 65-year-old with 1.5 cm HR+/HER2–, AUS-negative tumor?
    • Discuss SLNB omission per ASCO 2025, referencing SOUND / INSEMA
    • Emphasize shared decision-making and document that nodal status won’t change systemic therapy / RNI plans
  • Does negative AUS define cN0 reliably enough to omit surgery?
    • In SOUND / INSEMA, AUS was adequate for selection:
      • Axillary failures were rare with omission when systemic / RT plans were appropriat:
        • Still, ensure imaging quality and consider biology.
• Pathology definitions and “what counts”
  • Define ITCs vs micrometastases (AJCC 8e):
    • ITCs:
      • < 0.2 mm or < 200 cells (N0[i+])
    • Micrometastases:
      • 0.2 mm to 2 mm (N1mi)
  • Management parallels the trials:
    • Micrometastases (IBCSG 23-01) often no ALND:
      • ITCs generally node-negative 
  • Do ITCs change indications for ALND or RNI
    • ITCs typically do not mandate ALND:
      • Decisions on RNI hinge on comprehensive risk assessment rather than ITCs alone (Use institutional protocols) 
• Neoadjuvant chemotherapy (NAC): SLNB and TAD
  • ACOSOG Z1071 – what did we learn?
    • In biopsy-proven cN1→ycN0 after NAC:
      • SLNB had an FNR ≈ 12%:
        • Improved by dual tracer and retrieving ≥ 3 SLNs
        • Capturing the clipped node lowered the FNR further – ushering in targeted axillary dissection (TAD) 
  • SENTINA – why was FNR a concern?
    • Complex 4-arm RCT showed higher FNRs when SLNB was performed after NAC in initially node-positive patients, especially when only 1 to 2 SLNs were retrieved:
      • Driving optimization:
        • Dual mapping, ≥ 3 SLNs and TAD
  • SN-FNAC (JCO 2015) – can SLNB be accurate post-NAC in cN+?
    • With mandatory IHC, ID rate 87.6% and FNR 8.4%:
      • When ≥ 2 SLNs were removed – evidence that optimized technique can make SLNB acceptable after NAC in prior cN+
  • GANEA-2 (2019) – safety signal?
    • Prospective multicenter study supported feasibility and safety of post-NAC SLNB with low axillary failure when using optimized protocols; informs modern post-NAC algorithms
  • What is TAD and why do it?
    • Targeted axillary dissection combines SLNB + removal of the pre-treatment clipped node:
      • To slash FNR vs SLNB alone and better mirror basin response – core idea from MD Anderson implementation work 
  • RISAS / TAD accuracy – what’s the FNR
    • Multicenter diagnostic study of radioactive iodine seed localization (RISAS):
      • FNR 3.5%, NPV 92.8% – strong diagnostic performance for restaging after NAC 
  • MARI protocol – how is it different?
    • Marking the positive node with a seed pre-NAC and excising it post-NAC; with PET-CT integration:
      • MARI can avoid ALND in ~80% of cN+ while keeping 3-yr axillary recurrence-free interval ~98%
  • TAD outcomes – can we safely omit ALND in responders?
    • Cohorts show low 3-yr axillary recurrence with TAD alone in good responders (and no survival decrement vs TAD + ALND in selected patients):
      • Supporting ALND omission after accurate TAD
  • Practical NAC pearls to minimize FNR:
    • Always clip the biopsied positive node pre-NAC
    • Use dual / multi-tracers
    • Aim to remove clipped node + ≥ 2 to 3 SLNs
    • Consider seed / mag / wire techniques to ensure clipped-node retrieval
  • What if the clipped node is not a sentinel node?
    • Happens in ~ 20% to 25% – hence TAD’s value:
    • Explicitly localize and remove the clipped node in addition to SLNs to mitigate mapping discordance
  • “Lost marker” after NAC – how common and what to do?
    • About 6% markers cannot be retrieved:
      • Have contingency plans:
        • Intra-op imaging
        • Secondary localization
        • Proceed to ALND if residual disease risk is high and target cannot be verified 
  • After NAC, who still needs ALND?
    • Persistent palpable / yrcN+ disease
    • Inadequate TAD / SLN retrieval
    • Gross ECE / bulky residual nodal disease
    • Tailor with imaging, pathology, and MDT input
• Radiotherapy interplay and guidelines:
  • When you omit ALND after positive SLN, what about RT?
    • Trials (AMAROS, OTOASOR):
      • Delivered axillary / RNI with excellent control and less lymphedema than ALND
    • For mastectomy with 1 to 2 SLN macrometastases:
      • RNI without ALND is supported (now reflected in 2025 PMRT guidance)
  • 2025 ASTRO-ASCO-SSO PMRT update – what changed?
    • Reaffirms PMRT in most node-positive after mastectomy
    • Clarifies post-NAC ypN0 and scope of RNI:
      • Emphasizes integration with less invasive axillary surgery to limit morbidity
  • Does RNI obviate ALND in all scenarios?
    • No:
      • Use patient selection akin to AMAROS /SENOMAC (limited macrometastases burden)
      • Bulky residual disease or inadequate mapping still tips to ALND
• Special populations and situations:
  • Age ≥ 70, small HR+ / HER2- tumors – do I need SLNB?
    • SSO Choosing Wisely and ASBrS support omitting axillary staging when it won’t change adjuvant therapy:
      • Aligns with ASCO 2025 omission framework
  • DCIS – when is SLNB indicated?
    • Not for BCS without invasion suspicion
    • Do SLNB for mastectomy or if imaging / biopsy suggests invasion risk
  • Re-SLNB after prior surgery?
    • Feasible after prior BCS / SLNB:
      • But results may not alter systemic therapy in local recurrences:
        • Individualize
  • Pregnancy – map with what tracer?
    • Avoid radiocolloid if possible depending on local policy
    • Many centers use blue dye cautiously (risk of anaphylaxis)
      • Institutional / obstetric MDT policy applies; outside trial scope
  • Male breast cancer – apply same axillary principles?
    • Generally yes:
      • SENOMAC included men without a signal of harm from ALND omission in selected cases
• Minimum SLNs to retrieve?
  • Strive for ≥ 2
  • ≥ 3 post-NAC if possible – associated with lower FNR in SENTINA / ACOSOG Z1071:
    • Ensure robust mapping
• Mapping – dye alone acceptable?
  • Dual tracer is preferred for lowest FNR
  • Dye-only can work but increases FNR / variability – reserve for exceptional logistics Does extracapsular extension (ECE) mandate ALND?
• Does extracapsular extension (ECE) mandate ALND?
  • Not categorically:
    • SENOMAC included some ECE without harming noninferiority
    • Consider extent (gross vs microscopic) and planned RNI
• Two vs three positive SLNs in BCS – Z0011 boundary?
  • >2 positive SLNs (or Z0011-ineligible features):
    • Generally push toward further axillary therapy:
      • Often ART / RNI rather than routine ALND 
• Mastectomy, 1 to 2 macrometastases SLNs – can I do SLNB alone + RNI?
  • Yes – supported by AMAROS and SENOMAC:
    • Many centers omit ALND and deliver comprehensive RNI
• Micrometastases (≤ 2 mm) after SLNB – ALND needed?
  • No:
    • IBCSG 23-01 provides level-1 evidence to omit ALND:
      • Manage with breast / RT decisions as appropriate
• ITCs only – how to code / manage?
  • N0(i+):
    • Do not count as node-positive for N category:
      • Decisions about RT / systemic therapy rely on whole-patient risk
• Post-NAC, cN1→ycN0 with TAD negative – omit ALND?
  • Yes for many:
    • With robust TAD (clipped node retrieved + SLNs) showing pCR / low burden:
      • ALND can be omitted:
        • Early outcomes show low axillary failure
• Post-NAC, ypN1mi – what’s the move?
  • Case-by-case:
    • Limited data
    • Many MDTs favor RNI and omit ALND if TAD robust and burden minimal:
      • Document rationale (biology, response, fields):
        • See ASBrS resource guide framing individualized decisions
• When is pre-NAC SLNB appropriate?
  • Avoid:
    • Image-guided needle biopsy / clip suspicious nodes before NAC and stage after NAC with SLNB / TAD
• Does adding axillary RT after TAD-negative improve outcomes?
  • Uncertain; trials ongoing:
    • Observational data suggest very low axillary recurrence with accurate TAD even without ALND:
      • RT decisions are individualized
• Acceptable axillary failure rates with de-escalation?
  • Across ACOSOG Z0011 / AMAROS / OTOASOR /SOUND / INSEMA:
    • Axillary recurrences are ~ 1% to 2% range at mid-term, with no survival penalty – key benchmark when counseling
• Documentation when omitting SLNB in 2025
  • Record AUS quality / negative, eligibility per ASCO 2025 & SOUND / INSEMA:
    • That nodal status won’t alter systemic / RT plan, and shared decision-making
      
• How do European trials generalize to a diverse US population?
  • Biology and systemic therapy drive outcomes; de-escalation trials show consistency across subgroups
  • Apply trial entry criteria, use high-quality AUS, and partner with RNI where trials did:
    • Guideline-concordant practice mitigates external validity concerns
• What’s on the horizon (TAXIS)?
  • TAXIS tests tailored axillary surgery (remove clipped + sentinel nodes; omit ALND) with RNI in cN+:
    • Continuing the move away from full ALND where disease control is maintained
  • Blue dye vs radiocolloid vs ICG – does tracer choice change outcomes?
    • Dual tracer (radiocolloid + blue) remains the most validated for lowest FNR
    • ICG is promising, especially post-NAC, but data are heterogeneous
    • Choose the approach that maximizes node yield in your OR
• What lymphedema differences matter in clinic?
  • Expect lowest rates with no axillary surgery (SOUND / INSEMA) or SLNB alone
  • Intermediate with ART / RNI
  • Highest with ALND (AMAROS quantified 11% vs 23% at 5 yr)
    • Use this in counseling
• After prophylactic mastectomy, should we stage the axilla?
  • No:
    • SLNB is not recommended during prophylactic mastectomy given the very low chance of invasive cancer / nodal disease 
• Relevance of ACOSOG Z0011 to mastectomy patients?
  • Z0011 enrolled BCS + whole-breast RT
  • For mastectomy, lean on AMAROS and SENOMAC to omit ALND with planned RNI for 1 to 2 macrometastases
• One-slide algorithm to operationalize (2025):
  • Upfront cN0, AUS negative, small HR+ / HER2 negative:
    • Consider omit SLNB (ASCO 2025):
      • Else SLNB
  • 1 to 2 SLN macrometastases:
    • Omit ALND
    • BCS → usually radiation tangents ± RNI
  • Mastectomy → RNI (AMAROS/SENOMAC)
  • NAC cN1→ycN0 → TAD (clip+SLNs):
    • If negative / low burden:
      • Omit ALND; tailor RNI
    • Persistent cN+, bulky / ECE, mapping failure:
      • ALND
• Quick source keys (selected):
  • SLNB vs ALND:
    • NSABP B-32, ALMANAC, Milan
  • No ALND (positive SLN):
    • ACOSOG Z0011; IBCSG 23-01 (micrometastases); AMAROS; OTOASOR
  • No SLNB:
    • SOUND; INSEMA; ASCO 2025
  • Post-NAC:
    • ACOSG Z1071; SENTINA; SN-FNAC; GANEA-2; TAD / RISAS / MARI
  • Guidelines (2024–2025):
    • ASCO 2025 SLNB update; ASTRO-ASCO-SSO 2025 PMRT; ASBrS resource guide

The treatment landscape for HER2-positive early breast cancer (EBC) is evolving rapidly — and trastuzumab deruxtecan (T-DXd) is emerging as a potential new standard in both the neoadjuvant and adjuvant settings.

🔹 Neoadjuvant Setting

DESTINY-Breast11

T-DXd followed by THP (docetaxel + trastuzumab + pertuzumab) demonstrated:

Significantly higher pathologic complete response (pCR) rates compared with standard anthracycline-based regimens A chemotherapy-sparing strategy with reduced anthracycline exposure Favorable tolerability profile consistent with prior T-DXd data

📊 Early reports show pCR rates approaching ~65–70%, exceeding historical benchmarks for standard neoadjuvant regimens (typically ~55–60%).

Clinical Implication:

We may be entering an era of antibody–drug conjugate (ADC)-based neoadjuvant intensification, potentially redefining the backbone of HER2-directed therapy.

Reference:

Hurvitz SA et al. DESTINY-Breast11. Presented at ESMO 2024 / SABCS 2024 (late-breaking data).

🔹 Adjuvant Setting

DESTINY-Breast05

For patients with residual invasive disease after neoadjuvant therapy, T-DXd demonstrated:

53% reduction in risk of invasive disease–free survival (iDFS) events compared with T-DM1 Superior invasive disease–free survival Manageable toxicity, with ILD rates consistent with prior experience

This builds upon the paradigm established by KATHERINE, where T-DM1 replaced trastuzumab in patients with residual disease.

Now, T-DXd appears poised to replace T-DM1 in this high-risk population.

Reference:

DESTINY-Breast05. Presented at ASCO 2025.

von Minckwitz G et al. KATHERINE trial. NEJM. 2019;380:617–628.

🔬 Why This Matters

We are witnessing:

A shift from monoclonal antibodies → ADC-based escalation Earlier deployment of highly potent HER2-directed agents Refinement of risk-adapted therapy based on response

If adopted into guidelines (NCCN, ASCO, ESMO), this could:

Redefine the management of residual disease Potentially reduce recurrence risk further in high-risk HER2+ EBC Change neoadjuvant sequencing strategies

⚠️ Considerations

ILD/pneumonitis risk requires vigilance Cost-effectiveness and long-term survival data pending Optimal sequencing with pertuzumab still being clarified

📌 Bottom Line

T-DXd is no longer just a metastatic drug.

It is rapidly reshaping the curative-intent HER2+ early breast cancer algorithm.

Choledochal Cysts – Types and Management

Choledochal cysts are congenital cystic dilatations of the biliary tree. They are associated with an abnormal pancreaticobiliary junction and carry a significant lifetime risk of malignancy (especially cholangiocarcinoma).

Classification (Todani Classification)

The most widely used system is the Todani classification, which divides choledochal cysts into five main types:

Type I – Extrahepatic bile duct dilatation (most common, 50–80%)
• Ia – Diffuse cystic dilatation of CBD
• Ib – Focal segmental dilatation
• Ic – Fusiform dilatation of CBD

Management:
→ Complete excision of extrahepatic bile duct + Roux-en-Y hepaticojejunostomy

Type II – True diverticulum of CBD
• Saccular outpouching from extrahepatic bile duct

Management:
→ Diverticulectomy ± primary closure of CBD

Type III – Choledochocele
• Intraduodenal dilatation of distal CBD (within ampulla)

Management:
→ Endoscopic sphincterotomy (often sufficient)
→ Surgical excision if large/symptomatic

Type IV – Multiple cysts
• IVa – Both intrahepatic and extrahepatic involvement
• IVb – Multiple extrahepatic cysts only

Management:
→ Excision of extrahepatic bile duct + Roux-en-Y hepaticojejunostomy
→ Liver resection if localized intrahepatic disease
→ Liver transplant if diffuse severe intrahepatic disease

Type V – Caroli Disease
• Multiple intrahepatic cystic dilatations only

Associated with congenital hepatic fibrosis.

Management:
→ Segmental liver resection (localized)
→ Liver transplantation (diffuse disease)

Clinical Presentation
• Children: classic triad (rarely complete)
• Abdominal pain
• Jaundice
• Palpable mass
• Adults:
• Recurrent cholangitis
• Pancreatitis
• Biliary colic
• Incidental finding

Investigations
• Ultrasound – initial test
• MRCP – investigation of choice
• CT if malignancy suspected
• LFTs

ERCP mainly therapeutic (type III).

Complications
• Cholangitis
• Pancreatitis
• Stones
• Strictures
• Rupture (rare)
• Cholangiocarcinoma (10–30% lifetime risk if untreated)

Principles of Management (Important for Practice)

1. Complete cyst excision whenever possible
2. Avoid drainage procedures (obsolete due to cancer risk)
3. Long-term follow-up due to residual malignancy risk
4. Early surgery in children once diagnosed

Surgical Standard Operation

Cyst excision + Roux-en-Y hepaticojejunostomy
→ Gold standard for Type I and IV

Mirizzi Syndrome: The rare but challenging complication where an impacted gallstone in the cystic duct or Hartmann’s pouch causes external compression or fistulization into the common bile duct. The modified Csendes classification grades severity from Type 1 (external compression only) through Type 5 (cholecystobiliary fistula with gallstone ileus). Type 1 shows simple compression without fistula formation. Type 2 involves erosion affecting less than one-third of the bile duct circumference. Type 3 extends to involve one-third to two-thirds of the duct. Type 4 shows complete destruction of the bile duct wall. Type 5 adds the complication of cholecystoenteric fistula with gallstone ileus. Recognition is critical during cholecystectomy as misidentification can lead to bile duct injury. Higher types require bile duct reconstruction

New 5-Year Evidence Supporting Radiofrequency Ablation (RFA) in Early-Stage Breast Cancer

I’m pleased to share results from the RAFAELO Phase 3 multicenter trial — published online in Annals of Surgical Oncology (Feb 18, 2026) — assessing radiofrequency ablation (RFA) as a minimally invasive alternative to partial mastectomy in early-stage breast cancer. 

🔍 Study Overview

• Design: Multicenter, single-arm, Phase 3 clinical study.

• Population: 370 women with solitary Tis–T1 (≤1.5 cm), N0M0 breast carcinomas.

• Intervention: Percutaneous RFA followed by whole-breast radiation (45–60 Gy).

• Primary Endpoint: 5-year ipsilateral breast tumor recurrence-free survival (IBTRFS). 

📈 Key Findings

✔ At 5 years, IBTRFS was 98.6% (90% CI 97.1–99.3%), exceeding the pre-specified noninferiority margin of 90%.

✔ Only 2 ipsilateral recurrences were observed at 5 years.

✔ Grade ≥3 skin ulceration was rare (1/370 patients), underscoring a favorable safety profile.

✔ These results suggest that RFA with adjuvant radiation may be comparable to partial mastectomy in appropriately selected early-stage patients. 

🏷 Clinical Significance

This large prospective trial provides the most robust long-term evidence to date that RFA — a less invasive approach — may be a viable local-control strategy in small, node-negative breast cancers. These findings reinforce ongoing interest in expanding treatment options that balance oncologic safety with patient-centred care (e.g., cosmesis, procedural morbidity). 

Optional Add-Ons for Engagement

🔹 Thanks to the RAFAELO Study Group and contributing centers for advancing patient-centred oncology. 

🔹 Looking forward to longer follow-up, quality-of-life data, and comparative trials against standard surgery

https://idp.springer.com/authorize?response_type=cookie&client_id=springerlink&redirect_uri=https%3A%2F%2Flink.springer.com%2Farticle%2F10.1245%2Fs10434-026-19220-0

• Conference Overview
  Held March 12–15, 2025 in Vienna with >3,100 global participants.
  Focused on early breast cancer (BC): evidence, controversies, consensus, and breakthroughs.
  Included lectures, debates, poster sessions, and the renowned St. Gallen Consensus Session.
  Hansjoerg Senn Memorial Lecture was introduced to honor a major contributor to BC care. 
  
  🔬 Systemic Therapy & Novel Agents
  Goal of early BC therapy is to improve overall survival (OS) through better systemic and local treatment.
  Surrogate endpoints (e.g., pathological complete response) are crucial for accelerating drug development.
  New endocrine therapies (SERDs) are being evaluated, with emphasis on QoL and resistance mechanisms.
  Anti-HER2 advances from metastatic setting are being translated to early BC, including adaptive trial designs.
  Antibody-drug conjugates (ADCs) hold potential in early BC; ongoing trials are evaluating various indications. 
  
  🧬 Liquid Biopsy & Biomarkers
  ctDNA and liquid biopsy show promise for minimal residual disease (MRD) detection and relapse risk stratification.
  Tumor-informed assays have higher sensitivity than tumor-agnostic panels.
  Circulating tumor cells (CTCs) are prognostic but less sensitive; CHIP mutations may confound results.
  Multiple trials are exploring ctDNA as a tool for guiding post-treatment strategies. 
  
  HER2+ Breast Cancer
  Trastuzumab remains a foundational therapy after 20 years.
  Duration of trastuzumab (6 vs. 12 months) continues to be debated; 12 months remains standard.
  Improved HER2 testing and classification helps tailor therapies, especially in HER2-low disease.
  De-escalation strategies (e.g., PET-adapted) are under study for selected patients.
  Residual disease post-neoadjuvant therapy moves toward T-DM1 or other combinations; new trials are ongoing. 
  
  Tailoring Treatment & De-Escalation
  Omitting radiotherapy (RT) or endocrine therapy (ET) in very low-risk patients is under investigation.
  Minimally invasive alternatives (e.g., cryoablation) are being evaluated to reduce surgical burden.
  Older patients need individualized decision making rather than age-based exclusion from therapy.
  Tools like ESMO Magnitude of Clinical Benefit Scale can help weigh benefits vs toxicity. 
  
  Surgery & Local Management
  Breast-conserving surgery (BCS) remains preferred when feasible; mastectomy does not guarantee survival benefit.
  Radiotherapy tailoring (partial, hypofractionation) reduces toxicity while maintaining control.
  Post-neoadjuvant surgery focuses on resection of residual disease; MRI radiomics and biopsies aid prediction.
  Reconstruction decisions must be individualized, involving patient preferences and RT considerations. 
  
  ER+ Disease Nuances
  Optimizing adjuvant therapy (ET, CDK4/6 inhibitors, genomic assays) depends on recurrence risk and biomarkers.
  Chemotherapy benefit varies by genomic risk scores and age—particularly in premenopausal women.
  Extended ET decisions benefit from clinical, genomic, and novel biomarkers like ctDNA.
  Invasive lobular carcinoma (ILC) and ER-low tumors need refined imaging and therapeutic stratification. 
  
  Artificial Intelligence (AI) Integration
  AI has potential to enhance:
  Biomarker discovery and response prediction
  Treatment planning and radiation delivery
  Target identification and clinical decision support
  Collaboration between AI developers and clinicians is essential for clinical implementation. 
  
  Imaging & Staging Updates
  PET-CT may be useful in higher-stage early BC; routine use in stage I remains limited.
  Breast MRI improves staging but increases interventions without clear outcome benefit; selective use recommended.
  Follow-up imaging remains guided by existing evidence; future strategies might integrate new technologies and ctDNA. 
  
  Hereditary BC & Prevention
  Germline mutations (BRCA1/2, PALB2, ATM, CHEK2) justify altered management and intensive screening.
  Risk-reducing surgeries lower incidence, though survival benefits require longer follow-up.
  Non-surgical options (e.g., intensified screening, risk-reducing medications) are important for many carriers. 
  
  Axillary Management
  Sentinel lymph node biopsy (SLNB) remains standard for clinically node-negative patients.
  Omission of upfront axillary surgery is considered in select scenarios with multidisciplinary input.
  Trials are evaluating safe approaches to avoid full axillary dissection post-neoadjuvant therapy. 
  
  Clinical Trials & Patient-Centered Design
  High-quality trials require real-world applicability, patient involvement, meaningful endpoints, and QoL measures.
  Trial design frameworks (e.g., SPIRIT, PRECIS-2) help balance explanatory vs pragmatic objectives. 
  
  Special Populations
  BC during pregnancy requires tailored imaging and therapy planning to optimize maternal and fetal safety.
  Young patients and those with reproductive concerns need individualized counseling and treatment adaptation. 

https://ecancer.org/en/journal/article/2075-the-19th-st-gallen-international-breast-cancer-conference-primary-therapy-of-patients-with-early-breast-cancer-evidence-controversies-consensus-key-moments-and-breakthroughs?utm_campaign=automated-emails&utm_source=siteupdates-en-html-20260213&utm_medium=email&utm_target=d8628274966ebe70f6f44ff9393f2797c2d952c553cc7fa3f43de5e1c17fd7171edb509c851169c954d77de3b71e4aa86c3e034376f2253f-f23386

Paper summary (Eur Arch Otorhinolaryngol, 2026) — “The impact of drains on surgical outcomes in thyroid surgery”

This is a meta-analysis of randomized controlled trials comparing drain vs no drain after adult thyroid surgery (search Jan 1995–Aug 2025). It included 10 RCTs (n=1,078) and assessed haematoma/seroma (primary) plus SSI, return-to-theatre, pain, and length of stay. 

Key findings

No significant difference with drains for: Haematoma (p=0.15) Seroma (p=0.64) Return-to-theatre (p=0.22)  Drains were associated with worse outcomes: Higher SSI (4.2% vs 0.5%, p=0.01) Longer LOS (≈ +1.2 days, p<0.0001) More pain (MD ≈ +2.2, p=0.001) 

Conclusion of the authors: routine drains don’t reduce clinically important collections/bleeding outcomes and should be selective/patient-specific. 

Additional high-yield evidence on the same question

Systematic reviews

2017 meta-analysis (14 studies, n=1,927): drains increased infection and length of stay, with no significant differences in haematoma/seroma or RLN palsy/hypoparathyroidism.  Cochrane review: highlights the key limitation of drains—they can block with clot and do not replace meticulous haemostasis / re-exploration when bleeding occurs; overall evidence did not support routine use. 

Randomized trials (examples)

2013 RCT (Uganda, n=68): no-drain group had shorter LOS and less pain, with no signal that drains prevented important complications.  2023 RCT (lobectomy + central neck dissection, n=104): no routine drain needed; no-drain group had shorter LOS and better comfort metrics. 

Evidence-based recommendation (practical)

1) Default position

For uncomplicated thyroidectomy/hemithyroidectomy, the best available RCT/meta-analysis evidence supports NO routine drain because it does not reduce haematoma/seroma and does increase SSI, pain, and LOS. 

2) When a drain may be reasonable (selective use)

Consider a drain selectively when you believe a drain will meaningfully manage expected ongoing output or permit monitoring in a high-risk scenario, e.g.:

Extensive dissection / large dead space (e.g., combined procedures, broad flap elevation) Significant intraoperative oozing despite optimization (coagulopathy, difficult hemostasis) Reoperative thyroid surgery Very large goiter/substernal component (case-dependent) Neck dissection / lateral compartment work (many surgeons drain these by default; note: classic drain trials often exclude lateral neck dissections) 

(Even in these settings, it’s worth emphasizing: drains don’t “prevent” a dangerous post-thyroidectomy hematoma—rapid recognition and evacuation remain key, and drains may clot off.) 

3) What to do instead of routine drains (high-impact steps)

Meticulous hemostasis + Valsalva before closure Layered closure / dead-space minimization Standardized post-op neck checks and early warning protocol (swelling, tightness, voice change, stridor) Clear hematoma pathway (immediate bedside opening vs OR depending on severity/resources)

• Atypical ductal hyperplasia (ADH):
  • Is a benign proliferative breast lesion:
    • Characterized by filling and distention of ducts by dysplastic monotonous epithelial cells:
      • Forming architecturally complex patterns, including:
        • Cribriform-like secondary lumens or micropapillary formations
  • It is found in approximately 10% of benign breast biopsies
  • It confers a four-fold increased risk of subsequent breast cancer:
    • With a cumulative incidence approaching 30% at 25 years
• Definition and Histopathology:
  • ADH is defined by cytologic and architectural features:
    • Established by Page and colleagues in 1985
  • The lesion shows:
    • Proliferation of dysplastic, monotonous epithelial cells:
      • With architectural complexity and nuclear hyperchromasia
  • The key distinction from ductal carcinoma in situ (DCIS) is quantitative rather than qualitative:
    • ADH shares histologic features with low-grade DCIS but is less extensive
    • If the lesion meets criteria for DCIS in terms of quality but involves fewer than two ducts or measures less than 2 mm:
      • It is classified as ADH
  • This places ADH in a transitional zone between benign and malignant disease:
    • Making it a premalignant lesion
• Epidemiology:
  • ADH:
    • Is found in approximately 10% of core needle biopsy specimens with benign findings
  • Both atypical ductal and atypical lobular hyperplasia:
    • Occur with equal frequency and confer similar breast cancer risks
  • The lesion is typically discovered incidentally on screening mammography:
    • In asymptomatic women
• Risk Factors and Modifiers:
  • Younger age at diagnosis:
    • Is associated with higher subsequent breast cancer risk
  • Family history of breast cancer:
    • May increase risk, though data are conflicting
  • Number of atypical foci significantly impacts risk:
    • Women with ≥ 3 foci have a standardized incidence ratio (SIR) of 5.29 compared to 3.11 for a single focus
  • Dense breasts:
    • Increase risk compared to fatty breasts
• Imaging Characteristics:
  • ADH:
    • Has no pathognomonic imaging appearance and typically mimics findings seen in small cancers
  • Mammographic Features:
    • Clustered microcalcifications:
      • Are the most common finding directly correlated with ADH:
        • Present in 64% to 82% of cases
      • Calcifications of intermediate concern or higher probability of malignancy:
        • Are more frequent when ADH is associated with malignancy
    • May also present as masses, asymmetric densities, or architectural distortion
    • Direct mammographic-histologic correlation:
      • Occurs in approximately 41% of cases
  • Ultrasound Features:
    • Most lesions appear as hypoechoic masses (64%)
    • Irregular shape (51%) and microlobulated margins (49%)
    • No specific posterior acoustic features (53%)
    • Parallel orientation (57%)
    • Presence of calcifications on ultrasound is significantly associated with upgrade to malignancy
  • ADH lesions are typically assigned BI-RADS category 4 (suspicious abnormality):
    • Warranting tissue sampling by core needle biopsy
• Management:
  • Surgical Excision:
    • Surgical excision remains the standard of care for ADH diagnosed on core needle biopsy:
      • Due to upgrade rates of 15% to 30% to DCIS or invasive cancer
    • A 2020 meta-analysis of 6,458 lesions:
      • Found a 29% upgrade rate for surgically excised ADH
    • The Society of Surgical Oncology recommends routine excision:
      • Noting an upgrade rate of at least 20%
  • Emerging Evidence for Selective Observation:
    • Recent literature suggests that select low-risk ADH lesions may be candidates for observation rather than routine excision:
      • Lesions that appear completely removed at biopsy
      • Limited foci:
        • Fewer than 2 to 3 foci
      • No necrosis or significant atypia on pathology
      • Small groups of mammographic calcifications
      • No enhancement on MRI
      • No underlying risk factors:
        • No history of breast cancer
        • No genetic mutation
        • No concurrent high-risk lesions
  • A 2022 study found that selected women with ADH who met predetermined low-risk criteria and were managed nonoperatively:
    • Had a 1.2% index site cancer rate at median 5.2-year follow-up:
      • Comparable to the 1.5% rate in those who underwent surgery
  • A 2025 study applying COMET trial criteria:
    • Found only a 3.43% upgrade to invasive disease in low-risk patients
• Post-Diagnosis Management:
  • For women with confirmed ADH on excisional biopsy:
    • Enhanced surveillance:
      • Annual mammography plus breast MRI screening
    • Risk-reducing medications:
      • Endocrine therapy (tamoxifen or aromatase inhibitors) is strongly recommended by NCCN guidelines:
      • With an 86% risk reduction for women with atypical hyperplasia
    • Lifestyle modifications:
      • Counseling on healthy lifestyle factors
  • Prognosis:
    • ADH confers a relative risk of approximately 4 for future breast cancer compared to women without the diagnosis
    • The absolute risk is substantial and sustained over time:
      • Cumulative Breast Cancer Incidence:
        • 5 years: 6.6% (95% CI 4.4-9.7%)
        • 10 years: 13.9% (95% CI 7.8-23.6%)
        • 25 years: 30% (either DCIS or invasive cancer)
      • The 10-year cumulative incidence is approximately 14.6%:
        • Representing about 1% per year
      • Risk increases with the number of atypical foci present:
        • Women with ≥ 3 foci have nearly double the risk of those with a single focus
    • Important Prognostic Considerations:
      • Risk affects both the ipsilateral and contralateral breast:
        • Though ipsilateral risk may be slightly higher
      • The risk does not plateau but continues to increase linearly over decades
      • Approximately half of subsequent breast cancers:
        • Occur within the first 5 years after ADH diagnosis
      • Both DCIS and invasive cancer contribute to subsequent events
      • The NCCN Breast Cancer Risk Reduction guidelines:
        • Classify women with atypical hyperplasia as high-risk and recommend risk-reducing endocrine therapy for those with life expectancy ≥ 10 years, given the substantial and sustained elevation in breast cancer risk
• References:
  • Atypical Hyperplasia of the Breast — Risk Assessment and Management Options. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. The New England Journal of Medicine. 2015;372(1):78-89. doi:10.1056/NEJMsr1407164.
  • Updates on Management of Atypical Hyperplasia of the Breast. Klassen CL, Fraker JL, Pruthi S. Mayo Clinic Proceedings. 2025;100(6):1051-1057. doi:10.1016/j.mayocp.2025.01.029.
  • Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. Menes TS, Kerlikowske K, Lange J, et al. JAMA Oncology. 2017;3(1):36-41. doi:10.1001/jamaoncol.2016.3022.
  • Benign Breast Disease and Breast Cancer Risk in the Percutaneous Biopsy Era. Sherman ME, Vierkant RA, Winham SJ, et al. JAMA Surgery. 2024;159(2):193-201. doi:10.1001/jamasurg.2023.6382.
  • Atypical Hyperplasia of the Breast: Mammographic Appearance and Histologic Correlation. Helvie MA, Hessler C, Frank TS, Ikeda DM. Radiology. 1991;179(3):759-64. doi:10.1148/radiology.179.3.2027988.
  • Imaging Characteristics of and Multidisciplinary Management Considerations for Atypical Ductal Hyperplasia and Flat Epithelial Atypia: Review of Current Literature. Harper LK, Carnahan MB, Bhatt AA, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2023;43(10):e230016. doi:10.1148/rg.230016.
  • Atypical Ductal Hyperplasia Diagnosed at Sonographically Guided Core Needle Biopsy: Frequency, Final Surgical Outcome, and Factors Associated With Underestimation. Mesurolle B, Perez JC, Azzumea F, et al. AJR. American Journal of Roentgenology. 2014;202(6):1389-94. doi:10.2214/AJR.13.10864.
  • Mucocele-Like Tumors of the Breast as Cystic Lesions: Sonographic-Pathologic Correlation. Kim SM, Kim HH, Kang DK, et al. AJR. American Journal of Roentgenology. 2011;196(6):1424-30. doi:10.2214/AJR.10.5028.
  • Diagnosis of Columnar Cell Lesions and Atypical Ductal Hyperplasia by Ultrasound-Guided Core Biopsy: Findings Associated With Underestimation of Breast Carcinoma. Ahn HS, Jang M, Kim SM, et al. Ultrasound in Medicine & Biology. 2016;42(7):1457-63. doi:10.1016/j.ultrasmedbio.2016.02.009.
  • Society of surgical oncology medical student & trainee primer for breast surgical oncology. Marissa K. Boyle, Julia M. Selfridge, Rachel E. Sargent, et al.
    Upgrade Rate of Percutaneously Diagnosed Pure Atypical Ductal Hyperplasia: Systematic Review and Meta-Analysis of 6458 Lesions. Schiaffino S, Calabrese M, Melani EF, et al. Radiology. 2020;294(1):76-86. doi:10.1148/radiol.2019190748.
  • Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who Do Not Undergo Surgical Excision. Kilgore LJ, Yi M, Bevers T, et al. Annals of Surgery. 2022;276(6):e932-e936. doi:10.1097/SLA.0000000000004849.
  • Implications of the COMET Trial for the Management of Atypical Ductal Hyperplasia. Zaveri S, Sun SX, Bevers TB, Albarracin CT, Bedrosian I. Annals of Surgical Oncology. 2025;:10.1245/s10434-025-18236-2. doi:10.1245/s10434-025-18236-2.
  • Atypical Hyperplasia of the Breast: Clinical Cases and Management Strategies. Vegunta S, Mussallem DM, Kaur AS, Pruthi S, Klassen CL. Cleveland Clinic Journal of Medicine. 2023;90(7):423-431. doi:10.3949/ccjm.90a.22098.
    Breast Cancer Risk Reduction. National Comprehensive Cancer Network. Updated 2025-08-29.
  • Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update. Visvanathan K, Fabian CJ, Bantug E, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2019;37(33):3152-3165. doi:10.1200/JCO.19.01472.
    Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics and Gynecology. 2017;130(1):e1-e16. doi:10.1097/AOG.0000000000002158.
  • Atypical Ductal or Lobular Hyperplasia, Lobular Carcinoma in-Situ, Flat Epithelial Atypia, and Future Risk of Developing Breast Cancer: Systematic Review and Meta-Analysis. Baker J, Noguchi N, Marinovich ML, et al. Breast (Edinburgh, Scotland). 2024;78:103807. doi:10.1016/j.breast.2024.103807.
  • Trajectory of Subsequent Breast Cancer Diagnoses in a Diverse Patient Cohort With Breast Atypia. Limberg JN, Thomas SM, Dalton JC, et al. Annals of Surgical Oncology. 2024;31(11):7550-7558. doi:10.1245/s10434-024-15788-7.

A cutting-edge study published in npj Breast Cancer today reports validation of the HER2DX genomic test as a robust prognostic tool in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and a taxane (THP). 

🔬 What was done: Researchers combined real-world data from 215 patients across Spanish and Polish cohorts. They assessed baseline tumor tissue using the HER2DX assay to derive genomic scores linked to outcomes in patients receiving standard first-line HER2-targeted therapy (THP). 

📊 Key findings:

• A high ERBB2 mRNA score was associated with significantly longer progression-free and overall survival, as well as higher objective response rates — independent of traditional clinical variables. 

• The team developed a HER2DX metastatic prognostic score that outperformed ERBB2 mRNA levels alone in predicting outcomes, suggesting genomic profiling can further refine risk stratification in advanced disease. 

📈 Implications: This study supports the clinical utility of HER2DX in identifying patients with HER2-positive advanced breast cancer who might derive the greatest benefit from existing first-line therapies — and highlights the growing role of genomic tools in precision oncology. 

Rodrigo Arrangoiz, MD

Surgical Oncologist, Mount Sinai Medical Center (MSMC)

Head & Neck and Breast Cancer Specialist

https://www.nature.com/articles/s41523-026-00909-0